The CONVERT trial showed that twice-daily (BD) concurrent chemoradiotherapy should continue to be considered the standard of care in localised LS-SCLC. A survey was conducted to assess the impact of the CONVERT trial in clinical practice and to identify any relevant research questions for future trials in this setting.
Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey
Novello, Silvia;
2019-01-01
Abstract
The CONVERT trial showed that twice-daily (BD) concurrent chemoradiotherapy should continue to be considered the standard of care in localised LS-SCLC. A survey was conducted to assess the impact of the CONVERT trial in clinical practice and to identify any relevant research questions for future trials in this setting.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Current management of limited-stage SCLC and CONVERT trial impact_ Results of the EORTC Lung Cancer Group survey _ Elsevier Enhanced Reader.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
2.05 MB
Formato
Adobe PDF
|
2.05 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
